Wenn man es wüsste ob der Kurs auf die 0,02$ fällt oder wieder auf die 0,2$ steigt!
Top-News
Neuester,
zuletzt geles. Beitrag
Antworten | Hot-Stocks-Forum Übersicht
Zurück
Weiter
... 77 78 79 81 82 83 ...
Antworten | Hot-Stocks-Forum Übersicht
Zurück
Weiter ... 77 78 79 81 82 83 ...
CANNABIS SCIENCE - Revolution oder Verblendung ?
Beiträge: 3.519
Zugriffe: 673.424 / Heute: 295
Zugriffe: 673.424 / Heute: 295
|
Werbung
Entdecke die beliebtesten ETFs von Amundi
Lyxor Net Zero 2050 S&P World Climate PAB (DR) UCITS ETF Acc
Perf. 12M: +206,18%
Amundi Nasdaq-100 Daily (2x) Leveraged UCITS ETF - Acc
Perf. 12M: +75,36%
Amundi ETF Leveraged MSCI USA Daily UCITS ETF - EUR (C/D)
Perf. 12M: +59,57%
Amundi Japan TOPIX II UCITS ETF - EUR Hedeged Dist
Perf. 12M: +37,65%
Amundi MSCI India II UCITS ETF - EUR Acc
Perf. 12M: +37,47%
Auf Trendwende muss man noch lange warten,die wird erst in 2018 kommen,bald tauchen wir noch tiefer ein.0,02-0,03 Cent kommen.!!
bin raus über U.S.A.
WL und Wiedereinstieg zwischen 2-3 Cents
WL und Wiedereinstieg zwischen 2-3 Cents
auf die 0,02 Cent um mich dann für nächstes Jahr richtig gut einzudecken.
web.tmxmoney.com/...id=6648260585577871&qm_symbol=CBIS:US
web.tmxmoney.com/...id=6648260585577871&qm_symbol=CBIS:US
dann tippe ich auf knapp unter 6 €Cent heute und 7-8 nächste Woche.
CBIS news out--Cannabis Science Calls on All MMJ Companies to Recognize and Join the Fight Against Opioid Addiction and Deaths by Supporting Self-Medicating Patients to fight Opioid Abuse by Using all Forms of Ingested MMJ as a Viable Gateway out of Extreme Opioid Usage
JAMA Internal Medicine Published an Astounding 25% Drop in Opioid Overdose Deaths in States with Medical Cannabis Laws on the Books for MMJ Self-Medicating Patient Usage
IRVINE, CA -- (Marketwired) -- 06/28/17 -- Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, calls on all MMJ Companies to recognize and join in the fight against Opioid Addiction and Deaths by educating and supporting their self-medicating patients to fight opioid over-usage by using all forms of ingested MMJ as a Gateway out of Extreme Opioid Usage.
Last fall, a study published in JAMA Internal Medicine found a 25% drop in opioid overdose deaths in states with medical cannabis laws on the books. To explain this effect, addiction researcher Amanda Reiman cites cannabis' applications for helping people quit harder drugs. As TIME reported last summer, a University of Georgia review of all Medicare Part D prescription filings between 2010 and 2013 found that states with legalized medicinal marijuana laws saw significant drops in prescriptions for pain medication, as well as for antidepressants, seizure medication, anxiety medication, sleep aids, and anti-nausea drugs, among others.
"Much has been written about the epidemic of opioid use and the increase in overdose mortality in the US. However, relatively less attention has focused on how the availability of alternative non-opioid treatments may affect overdose rates. Using cannabis to treat acute pain is familiar territory. Anecdotally, we've heard about patients replacing prescription drugs with cannabis as a gateway out. This could either be due to the fact that's it a drug with a fewer amount of side effects or it supports the ability to avoid using alcohol or illicit substances in combinations. There are many different cannabis-based medication strengths available, self-medicating patients should consider their condition and capabilities before they choose their method of delivery and dosage strengths as each combination has a different effect on different people. Some even say that cannabis gives them mindfulness and the ability to take a step back and think about what they're doing, or about to do. But if you're taking the step to wean yourself off a hard drug, you'll need all the support you can get. Cannabis also helps with symptoms like nausea, tremors, and insomnia. Approximately 60% of all opioid analgesic overdoses occur among patients who have legitimate prescriptions from a single provider. This group may be sensitive to medical cannabis laws; patients with chronic non-cancer pain who would have otherwise initiated opioid analgesics may choose medical cannabis instead," confirms, Dr. Allen Herman, Chief Medical Officer, (CMO), Cannabis Science Inc.
Nearly 50,000 Americans die by drug overdose each year, but that fact is not as simple as it may seem. Most of these deaths are caused not by illegal drugs such as heroin and cocaine but by prescription painkillers -- legal medication meant to help people, not kill them. Additionally, the use of opioid medications for the treatment of chronic pain is problematic because they cause other adverse effects when used for long periods, such as tolerance, hyperalgesia, and gastro-intestinal complications. As stated in an accompanying editorial to the JAMA Internal Medicine article, prescription opioids also have great abuse potential due to their influence on stress and reward circuits in the brain, promoting nonmedical use and abuse and diversion of prescription medications. That's a very serious problem. Roughly 20,000 people die of prescription overdoses annually in the United States, and opioid painkillers are the primary reason. Now the medical community is desperately looking to commercialize its new approaches to pain and addiction. Medical Marijuana, as it turns out, may be the best option as a gateway out of opioid addiction.
About Cannabis Science, Inc.
Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
JAMA Internal Medicine Published an Astounding 25% Drop in Opioid Overdose Deaths in States with Medical Cannabis Laws on the Books for MMJ Self-Medicating Patient Usage
IRVINE, CA -- (Marketwired) -- 06/28/17 -- Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, calls on all MMJ Companies to recognize and join in the fight against Opioid Addiction and Deaths by educating and supporting their self-medicating patients to fight opioid over-usage by using all forms of ingested MMJ as a Gateway out of Extreme Opioid Usage.
Last fall, a study published in JAMA Internal Medicine found a 25% drop in opioid overdose deaths in states with medical cannabis laws on the books. To explain this effect, addiction researcher Amanda Reiman cites cannabis' applications for helping people quit harder drugs. As TIME reported last summer, a University of Georgia review of all Medicare Part D prescription filings between 2010 and 2013 found that states with legalized medicinal marijuana laws saw significant drops in prescriptions for pain medication, as well as for antidepressants, seizure medication, anxiety medication, sleep aids, and anti-nausea drugs, among others.
"Much has been written about the epidemic of opioid use and the increase in overdose mortality in the US. However, relatively less attention has focused on how the availability of alternative non-opioid treatments may affect overdose rates. Using cannabis to treat acute pain is familiar territory. Anecdotally, we've heard about patients replacing prescription drugs with cannabis as a gateway out. This could either be due to the fact that's it a drug with a fewer amount of side effects or it supports the ability to avoid using alcohol or illicit substances in combinations. There are many different cannabis-based medication strengths available, self-medicating patients should consider their condition and capabilities before they choose their method of delivery and dosage strengths as each combination has a different effect on different people. Some even say that cannabis gives them mindfulness and the ability to take a step back and think about what they're doing, or about to do. But if you're taking the step to wean yourself off a hard drug, you'll need all the support you can get. Cannabis also helps with symptoms like nausea, tremors, and insomnia. Approximately 60% of all opioid analgesic overdoses occur among patients who have legitimate prescriptions from a single provider. This group may be sensitive to medical cannabis laws; patients with chronic non-cancer pain who would have otherwise initiated opioid analgesics may choose medical cannabis instead," confirms, Dr. Allen Herman, Chief Medical Officer, (CMO), Cannabis Science Inc.
Nearly 50,000 Americans die by drug overdose each year, but that fact is not as simple as it may seem. Most of these deaths are caused not by illegal drugs such as heroin and cocaine but by prescription painkillers -- legal medication meant to help people, not kill them. Additionally, the use of opioid medications for the treatment of chronic pain is problematic because they cause other adverse effects when used for long periods, such as tolerance, hyperalgesia, and gastro-intestinal complications. As stated in an accompanying editorial to the JAMA Internal Medicine article, prescription opioids also have great abuse potential due to their influence on stress and reward circuits in the brain, promoting nonmedical use and abuse and diversion of prescription medications. That's a very serious problem. Roughly 20,000 people die of prescription overdoses annually in the United States, and opioid painkillers are the primary reason. Now the medical community is desperately looking to commercialize its new approaches to pain and addiction. Medical Marijuana, as it turns out, may be the best option as a gateway out of opioid addiction.
About Cannabis Science, Inc.
Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
falls wir die 0,050€ überwinden kann es schnell nach oben gehen chartechnisch...
web.tmxmoney.com/...id=4916385620924382&qm_symbol=CBIS:US
Cannabis-Wissenschaft steigert den Kampf gegen Opioid-Drug-Sucht mit seinem anfänglichen Test-Batch von transdermalen Patches und Unisex-Rectal Suppositories, die jetzt in Los Angeles Dispensaries verfügbar sind und eine wachsende Nachfrage von Self-Medicating-Patienten treffen
IRCINE, CA - (Marketwired - Jul 7, 2017) - Cannabis Science, Inc. (OTC PINK: CBIS), ein US-Unternehmen, das sich auf die Entwicklung von Cannabis-basierten Medikamenten spezialisiert hat, freut sich, erste Testchargen von Transdermal Patches und Unisex Suppositorien Regime-Pakete sind jetzt in zwei Test-Apotheken in Los Angeles, Kalifornien, die die wachsende Nachfrage nach alternativen Schmerzmittel Liefermodule unter Selbst-medizinischen Patienten kämpfen mit mehreren Formen der chronischen Schmerz-Management, die das Unternehmen fest glaubt, wird direkt gegen die Opioid Medikamente überdosieren Pandemie.
Die CBIS Transdermal Patch wurde häufig von Selbstmediziner Patienten für fast alle verschiedenen Arten von chronischen Schmerzen einschließlich Fibromyalgie, diabetischen Nervenschmerzen, neuropathischen und viele andere Formen von kritischen Leiden, die mit chronischen Schmerzen verbunden sind, angefordert. Einer der Vorteile ist die Targeting-Wirkung, wie Cannabinoide in den Blutkreislauf am betroffenen Bereich durch Absorption der Haut eindringen und Formulierungen verabreicht werden, wenn Cannabinoide das zentrale Nervensystem durchdringen und dem Selbstmediziner die gewünschte Erleichterung verleihen.
Das CBIS Unisex Suppository Regimen Package ist ideal für Patienten, die an Krebsbehandlung Nebenwirkungen wie Übelkeit, Erbrechen, Schlaflosigkeit, Angst und starke Schmerzen leiden. Es fungiert auch als ein wirksames Ersatz-Delivery-System für Patienten, die Schwierigkeiten beim Einnehmen von Pillen oder Rauchen von Cannabis haben können, da die rektale Absorption eine höhere Bioverfügbarkeit bei gleichzeitiger gleichzeitiger Wirkung hervorruft. Die Zäpfchen sind die ersten von drei Regime-Pakete, die Cannabis Science für Patienten freisetzt, die alternative Abgabemethoden benötigen.
Nach dem Erhalt von Hunderten von Anfragen von eifrigen Selbst-medizinischen Patienten und Mitarbeiter im Gesundheitswesen, ist das Unternehmen stolz zu verkünden, dass sie jetzt zum Verkauf an der Kush Factory und Moonlight Cannabis Collective erhältlich sind.
Cannabis-Wissenschaft steigert den Kampf gegen Opioid-Drug-Sucht mit seinem anfänglichen Test-Batch von transdermalen Patches und Unisex-Rectal Suppositories, die jetzt in Los Angeles Dispensaries verfügbar sind und eine wachsende Nachfrage von Self-Medicating-Patienten treffen
IRCINE, CA - (Marketwired - Jul 7, 2017) - Cannabis Science, Inc. (OTC PINK: CBIS), ein US-Unternehmen, das sich auf die Entwicklung von Cannabis-basierten Medikamenten spezialisiert hat, freut sich, erste Testchargen von Transdermal Patches und Unisex Suppositorien Regime-Pakete sind jetzt in zwei Test-Apotheken in Los Angeles, Kalifornien, die die wachsende Nachfrage nach alternativen Schmerzmittel Liefermodule unter Selbst-medizinischen Patienten kämpfen mit mehreren Formen der chronischen Schmerz-Management, die das Unternehmen fest glaubt, wird direkt gegen die Opioid Medikamente überdosieren Pandemie.
Die CBIS Transdermal Patch wurde häufig von Selbstmediziner Patienten für fast alle verschiedenen Arten von chronischen Schmerzen einschließlich Fibromyalgie, diabetischen Nervenschmerzen, neuropathischen und viele andere Formen von kritischen Leiden, die mit chronischen Schmerzen verbunden sind, angefordert. Einer der Vorteile ist die Targeting-Wirkung, wie Cannabinoide in den Blutkreislauf am betroffenen Bereich durch Absorption der Haut eindringen und Formulierungen verabreicht werden, wenn Cannabinoide das zentrale Nervensystem durchdringen und dem Selbstmediziner die gewünschte Erleichterung verleihen.
Das CBIS Unisex Suppository Regimen Package ist ideal für Patienten, die an Krebsbehandlung Nebenwirkungen wie Übelkeit, Erbrechen, Schlaflosigkeit, Angst und starke Schmerzen leiden. Es fungiert auch als ein wirksames Ersatz-Delivery-System für Patienten, die Schwierigkeiten beim Einnehmen von Pillen oder Rauchen von Cannabis haben können, da die rektale Absorption eine höhere Bioverfügbarkeit bei gleichzeitiger gleichzeitiger Wirkung hervorruft. Die Zäpfchen sind die ersten von drei Regime-Pakete, die Cannabis Science für Patienten freisetzt, die alternative Abgabemethoden benötigen.
Nach dem Erhalt von Hunderten von Anfragen von eifrigen Selbst-medizinischen Patienten und Mitarbeiter im Gesundheitswesen, ist das Unternehmen stolz zu verkünden, dass sie jetzt zum Verkauf an der Kush Factory und Moonlight Cannabis Collective erhältlich sind.
der Boden ist nun erreicht :)
Werde nächste Woche auch wieder auf den Zug mit aufspringen :)
Werde nächste Woche auch wieder auf den Zug mit aufspringen :)
ganz klarer Ziel dann drei Jahren warten
Gelöschter Beitrag.
Einblenden
»
#2000 
|
Neueste Beiträge aus dem Cannabis Science Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
| 19 | AK 47;TOP 44;SKUNK-1000% tenbagger....... | Knallpatrone23 | S010711 | 25.04.21 03:24 | ||
7 | 1.456 | rebound eingeläutet!?? | ARTNER514 | Reecco | 25.04.21 02:01 | |
| 2 | 785 | Cannabis Science - kurz vor dem Durchbruch? | Mr.Cashh | famherzig | 25.04.21 01:21 | |
| 16 | 3.518 | CANNABIS SCIENCE - Revolution oder Verblendung ? | Brokerface030 | Reecco | 25.04.21 01:13 | |
| 151 | THC Therapeutics in einer Woche über + 350% | Temesta | Mr.Cashh | 24.04.21 23:45 |
